{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T18:39:04Z","timestamp":1794335944727,"version":"4.9.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1038\/s41591-019-0412-8","type":"journal-article","created":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T12:06:04Z","timestamp":1554120364000},"page":"547-553","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":242,"title":["Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic"],"prefix":"10.1038","volume":"25","author":[{"given":"Marina","family":"Caskey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel C.","family":"Nussenzweig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,1]]},"reference":[{"key":"412_CR1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1146\/annurev-immunol-051116-052433","volume":"35","author":"S Bournazos","year":"2017","unstructured":"Bournazos, S., Wang, T. T., Dahan, R., Maamary, J. & Ravetch, J. V. Signaling by antibodies: recent progress. Annu. Rev. Immunol. 35, 285\u2013311 (2017).","journal-title":"Annu. Rev. Immunol."},{"key":"412_CR2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/19420862.2018.1556465","volume":"11","author":"H Kaplon","year":"2019","unstructured":"Kaplon, H. & Reichert, J. M. Antibodies to watch in 2019. MAbs 11, 219\u2013238 (2019).","journal-title":"MAbs"},{"key":"412_CR3","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature01470","volume":"422","author":"X Wei","year":"2003","unstructured":"Wei, X. et al. Antibody neutralization and escape by HIV-1. Nature 422, 307\u2013312 (2003).","journal-title":"Nature"},{"key":"412_CR4","doi-asserted-by":"crossref","first-page":"4144","DOI":"10.1073\/pnas.0630530100","volume":"100","author":"DD Richman","year":"2003","unstructured":"Richman, D. D., Wrin, T., Little, S. J. & Petropoulos, C. J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl Acad. Sci. USA 100, 4144\u20134149 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"412_CR5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1089\/aid.1994.10.359","volume":"10","author":"A Buchacher","year":"1994","unstructured":"Buchacher, A. et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retroviruses 10, 359\u2013369 (1994).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"412_CR6","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1126\/science.7973652","volume":"266","author":"DR Burton","year":"1994","unstructured":"Burton, D. R. et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266, 1024\u20131027 (1994).","journal-title":"Science"},{"key":"412_CR7","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1128\/JVI.70.2.1100-1108.1996","volume":"70","author":"A Trkola","year":"1996","unstructured":"Trkola, A. et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70, 1100\u20131108 (1996).","journal-title":"J. Virol."},{"key":"412_CR8","doi-asserted-by":"crossref","first-page":"10892","DOI":"10.1128\/JVI.75.22.10892-10905.2001","volume":"75","author":"MB Zwick","year":"2001","unstructured":"Zwick, M. B. et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75, 10892\u201310905 (2001).","journal-title":"J. Virol."},{"key":"412_CR9","doi-asserted-by":"crossref","first-page":"7538","DOI":"10.1128\/JVI.66.12.7538-7542.1992","volume":"66","author":"MK Gorny","year":"1992","unstructured":"Gorny, M. K. et al. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J. Virol. 66, 7538\u20137542 (1992).","journal-title":"J. Virol."},{"key":"412_CR10","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nm1244","volume":"11","author":"A Trkola","year":"2005","unstructured":"Trkola, A. et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11, 615\u2013622 (2005).","journal-title":"Nat. Med."},{"key":"412_CR11","doi-asserted-by":"crossref","first-page":"11016","DOI":"10.1128\/JVI.01340-07","volume":"81","author":"S Mehandru","year":"2007","unstructured":"Mehandru, S. et al. Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection. J. Virol. 81, 11016\u201311031 (2007).","journal-title":"J. Virol."},{"key":"412_CR12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jim.2008.11.012","volume":"343","author":"JF Scheid","year":"2009","unstructured":"Scheid, J. F. et al. A method for identification of HIV gp140 binding memory B cells in human blood. J. Immunol. Methods 343, 65\u201367 (2009).","journal-title":"J. Immunol. Methods"},{"key":"412_CR13","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1126\/science.1241144","volume":"341","author":"F Klein","year":"2013","unstructured":"Klein, F. et al. Antibodies in HIV-1 vaccine development and therapy. Science 341, 1199\u20131204 (2013).","journal-title":"Science"},{"key":"412_CR14","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.cell.2014.01.052","volume":"156","author":"AP West Jr.","year":"2014","unstructured":"West, A. P. Jr. et al. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell 156, 633\u2013648 (2014).","journal-title":"Cell"},{"key":"412_CR15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nri.2017.148","volume":"18","author":"LM Walker","year":"2018","unstructured":"Walker, L. M. & Burton, D. R. Passive immunotherapy of viral infections: \u2018super-antibodies\u2019 enter the fray. Nat. Rev. Immunol. 18, 297\u2013308 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"412_CR16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/imr.12075","volume":"254","author":"JR Mascola","year":"2013","unstructured":"Mascola, J. R. & Haynes, B. F. HIV-1 neutralizing antibodies: understanding nature\u2019s pathways. Immunol. Rev. 254, 225\u2013244 (2013).","journal-title":"Immunol. Rev."},{"key":"412_CR17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev-med-061016-041032","volume":"69","author":"L Gama","year":"2018","unstructured":"Gama, L. & Koup, R. A. New-generation high-potency and designer antibodies: role in HIV-1 treatment. Annu. Rev. Med. 69, 409\u2013419 (2018).","journal-title":"Annu. Rev. Med."},{"key":"412_CR18","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1187659","volume":"329","author":"X Wu","year":"2010","unstructured":"Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856\u2013861 (2010).","journal-title":"Science"},{"key":"412_CR19","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1126\/science.1207227","volume":"333","author":"JF Scheid","year":"2011","unstructured":"Scheid, J. F. et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633\u20131637 (2011).","journal-title":"Science"},{"key":"412_CR20","doi-asserted-by":"crossref","first-page":"12669","DOI":"10.1128\/JVI.02213-14","volume":"88","author":"RS Rudicell","year":"2014","unstructured":"Rudicell, R. S. et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J. Virol. 88, 12669\u201312682 (2014).","journal-title":"J. Virol."},{"key":"412_CR21","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.immuni.2016.10.027","volume":"45","author":"J Huang","year":"2016","unstructured":"Huang, J. et al. Identification of a CD4-binding-site antibody to HIV that evolved near-pan neutralization breadth. Immunity 45, 1108\u20131121 (2016).","journal-title":"Immunity"},{"key":"412_CR22","doi-asserted-by":"crossref","first-page":"E3268","DOI":"10.1073\/pnas.1217207109","volume":"109","author":"H Mouquet","year":"2012","unstructured":"Mouquet, H. et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc. Natl Acad. Sci. USA 109, E3268\u2013E3277 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"412_CR23","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nature10373","volume":"477","author":"LM Walker","year":"2011","unstructured":"Walker, L. M. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466\u2013470 (2011).","journal-title":"Nature"},{"key":"412_CR24","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nature11544","volume":"491","author":"J Huang","year":"2012","unstructured":"Huang, J. et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491, 406\u2013412 (2012).","journal-title":"Nature"},{"key":"412_CR25","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.1128\/JVI.03246-15","volume":"90","author":"YD Kwon","year":"2016","unstructured":"Kwon, Y. D. et al. Optimization of the solubility of HIV-1-neutralizing antibody 10E8 through somatic variation and structure-based design. J. Virol. 90, 5899\u20135914 (2016).","journal-title":"J. Virol."},{"key":"412_CR26","doi-asserted-by":"crossref","first-page":"17624","DOI":"10.1073\/pnas.1415789111","volume":"111","author":"D Sok","year":"2014","unstructured":"Sok, D. et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc. Natl Acad. Sci. USA 111, 17624\u201317629 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"412_CR27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature13036","volume":"509","author":"NA Doria-Rose","year":"2014","unstructured":"Doria-Rose, N. A. et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509, 55\u201362 (2014).","journal-title":"Nature"},{"key":"412_CR28","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/355728a0","volume":"355","author":"EA Emini","year":"1992","unstructured":"Emini, E. A. et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355, 728\u2013730 (1992).","journal-title":"Nature"},{"key":"412_CR29","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1128\/JVI.73.5.4009-4018.1999","volume":"73","author":"JR Mascola","year":"1999","unstructured":"Mascola, J. R. et al. Protection of Macaques against pathogenic simian\/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73, 4009\u20134018 (1999).","journal-title":"J. Virol."},{"key":"412_CR30","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/72318","volume":"6","author":"JR Mascola","year":"2000","unstructured":"Mascola, J. R. et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1\/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6, 207\u2013210 (2000).","journal-title":"Nat. Med."},{"key":"412_CR31","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1128\/JVI.65.7.3514-3520.1991","volume":"65","author":"R Shibata","year":"1991","unstructured":"Shibata, R. et al. Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells. J. Virol. 65, 3514\u20133520 (1991).","journal-title":"J. Virol."},{"key":"412_CR32","first-page":"639","volume":"5","author":"J Li","year":"1992","unstructured":"Li, J., Lord, C. I., Haseltine, W., Letvin, N. L. & Sodroski, J. Infection of cynomolgus monkeys with a chimeric HIV-1\/SIVmac virus that expresses the HIV-1 envelope glycoproteins. J. Acquir. Immune Defic. Syndr. 5, 639\u2013646 (1992).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"412_CR33","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/00126334-200307010-00003","volume":"33","author":"R Pal","year":"2003","unstructured":"Pal, R. et al. Characterization of a simian human immunodeficiency virus encoding the envelope gene from the CCR5-tropic HIV-1 Ba-L. J. Acquir. Immune Defic. Syndr. 33, 300\u2013307 (2003).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"412_CR34","doi-asserted-by":"crossref","first-page":"8516","DOI":"10.1128\/JVI.00644-12","volume":"86","author":"R Gautam","year":"2012","unstructured":"Gautam, R. et al. Pathogenicity and mucosal transmissibility of the R5-tropic simian\/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies. J. Virol. 86, 8516\u20138526 (2012).","journal-title":"J. Virol."},{"key":"412_CR35","doi-asserted-by":"crossref","first-page":"8340","DOI":"10.1128\/JVI.75.17.8340-8347.2001","volume":"75","author":"PW Parren","year":"2001","unstructured":"Parren, P. W. et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian\/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75, 8340\u20138347 (2001).","journal-title":"J. Virol."},{"key":"412_CR36","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1128\/jvi.76.5.2123-2130.2002","volume":"76","author":"Y Nishimura","year":"2002","unstructured":"Nishimura, Y. et al. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J. Virol. 76, 2123\u20132130 (2002).","journal-title":"J. Virol."},{"key":"412_CR37","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1084\/jem.20132494","volume":"211","author":"M Shingai","year":"2014","unstructured":"Shingai, M. et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J. Exp. Med. 211, 2061\u20132074 (2014).","journal-title":"J. Exp. Med."},{"key":"412_CR38","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1080\/21645515.2018.1462640","volume":"14","author":"Y Huang","year":"2018","unstructured":"Huang, Y. et al. Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials. Hum. Vaccin. Immunother. 14, 2116\u20132127 (2018).","journal-title":"Hum. Vaccin. Immunother."},{"key":"412_CR39","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1097\/QAD.0000000000000298","volume":"28","author":"P Patel","year":"2014","unstructured":"Patel, P. et al. Estimating per-act HIV transmission risk: a systematic review. AIDS 28, 1509\u20131519 (2014).","journal-title":"AIDS"},{"key":"412_CR40","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/nm.1974","volume":"15","author":"AJ Hessell","year":"2009","unstructured":"Hessell, A. J. et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15, 951\u2013954 (2009).","journal-title":"Nat. Med."},{"key":"412_CR41","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature17677","volume":"533","author":"R Gautam","year":"2016","unstructured":"Gautam, R. et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature 533, 105\u2013109 (2016).","journal-title":"Nature"},{"key":"412_CR42","doi-asserted-by":"crossref","first-page":"6189","DOI":"10.1128\/JVI.00491-12","volume":"86","author":"B Moldt","year":"2012","unstructured":"Moldt, B. et al. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced Fc\u03b3RIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J. Virol. 86, 6189\u20136196 (2012).","journal-title":"J. Virol."},{"key":"412_CR43","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nature13612","volume":"514","author":"SY Ko","year":"2014","unstructured":"Ko, S. Y. et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 514, 642\u2013645 (2014).","journal-title":"Nature"},{"key":"412_CR44","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/s41591-018-0001-2","volume":"24","author":"R Gautam","year":"2018","unstructured":"Gautam, R. et al. A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection. Nat. Med. 24, 610\u2013616 (2018).","journal-title":"Nat. Med."},{"key":"412_CR45","doi-asserted-by":"crossref","first-page":"346","DOI":"10.4049\/jimmunol.176.1.346","volume":"176","author":"PR Hinton","year":"2006","unstructured":"Hinton, P. R. et al. An engineered human IgG1 antibody with longer serum half-life. J. Immunol. 176, 346\u2013356 (2006).","journal-title":"J. Immunol."},{"key":"412_CR46","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1074-7613(00)80043-6","volume":"10","author":"P Poignard","year":"1999","unstructured":"Poignard, P. et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 10, 431\u2013438 (1999).","journal-title":"Immunity"},{"key":"412_CR47","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature11604","volume":"492","author":"F Klein","year":"2012","unstructured":"Klein, F. et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492, 118\u2013122 (2012).","journal-title":"Nature"},{"key":"412_CR48","doi-asserted-by":"crossref","first-page":"16538","DOI":"10.1073\/pnas.1315295110","volume":"110","author":"JA Horwitz","year":"2013","unstructured":"Horwitz, J. A. et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc. Natl Acad. Sci. USA 110, 16538\u201316543 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"412_CR49","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1084\/jem.20130221","volume":"210","author":"R Diskin","year":"2013","unstructured":"Diskin, R. et al. Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies. J. Exp. Med. 210, 1235\u20131249 (2013).","journal-title":"J. Exp. Med."},{"key":"412_CR50","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1084\/jem.20141050","volume":"211","author":"F Klein","year":"2014","unstructured":"Klein, F. et al. Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants. J. Exp. Med. 211, 2361\u20132372 (2014).","journal-title":"J. Exp. Med."},{"key":"412_CR51","doi-asserted-by":"crossref","first-page":"eaal2144","DOI":"10.1126\/scitranslmed.aal2144","volume":"9","author":"NT Freund","year":"2017","unstructured":"Freund, N. T. et al. Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller. Sci. Transl. Med. 9, eaal2144 (2017).","journal-title":"Sci. Transl. Med."},{"key":"412_CR52","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nature12746","volume":"503","author":"M Shingai","year":"2013","unstructured":"Shingai, M. et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503, 277\u2013280 (2013).","journal-title":"Nature"},{"key":"412_CR53","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nature12744","volume":"503","author":"DH Barouch","year":"2013","unstructured":"Barouch, D. H. et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503, 224\u2013228 (2013).","journal-title":"Nature"},{"key":"412_CR54","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.cell.2014.07.043","volume":"158","author":"A Halper-Stromberg","year":"2014","unstructured":"Halper-Stromberg, A. et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 158, 989\u2013999 (2014).","journal-title":"Cell"},{"key":"412_CR55","doi-asserted-by":"crossref","first-page":"10447","DOI":"10.1128\/JVI.00049-13","volume":"87","author":"JP Jaworski","year":"2013","unstructured":"Jaworski, J. P. et al. Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques. J. Virol. 87, 10447\u201310459 (2013).","journal-title":"J. Virol."},{"key":"412_CR56","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nature21435","volume":"543","author":"Y Nishimura","year":"2017","unstructured":"Nishimura, Y. et al. Early antibody therapy can induce long-lasting immunity to SHIV. Nature 543, 559\u2013563 (2017).","journal-title":"Nature"},{"key":"412_CR57","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41586-018-0600-6","volume":"563","author":"EN Borducchi","year":"2018","unstructured":"Borducchi, E. N. et al. Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature 563, 360\u2013364 (2018).","journal-title":"Nature"},{"key":"412_CR58","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/infdis\/165.2.364","volume":"165","author":"D Vittecoq","year":"1992","unstructured":"Vittecoq, D. et al. Passive immunotherapy in AIDS: a randomized trial of serial human immunodeficiency virus-positive transfusions of plasma rich in p24 antibodies versus transfusions of seronegative plasma. J. Infect. Dis. 165, 364\u2013368 (1992).","journal-title":"J. Infect. Dis."},{"key":"412_CR59","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1089\/aid.1998.14.545","volume":"14","author":"LA Cavacini","year":"1998","unstructured":"Cavacini, L. A. et al. Phase I study of a human monoclonal antibody directed against the CD4-binding site of HIV type 1 glycoprotein 120. AIDS Res. Hum. Retroviruses 14, 545\u2013550 (1998).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"412_CR60","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00002030-200201250-00012","volume":"16","author":"C Armbruster","year":"2002","unstructured":"Armbruster, C. et al. A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1. AIDS 16, 227\u2013233 (2002).","journal-title":"AIDS"},{"key":"412_CR61","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/jac\/dkh428","volume":"54","author":"C Armbruster","year":"2004","unstructured":"Armbruster, C. et al. Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10\/2F5\/2G12. J. Antimicrob. Chemother. 54, 915\u2013920 (2004).","journal-title":"J. Antimicrob. Chemother."},{"key":"412_CR62","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nature14411","volume":"522","author":"M Caskey","year":"2015","unstructured":"Caskey, M. et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522, 487\u2013491 (2015).","journal-title":"Nature"},{"key":"412_CR63","doi-asserted-by":"crossref","first-page":"319ra206","DOI":"10.1126\/scitranslmed.aad5752","volume":"7","author":"RM Lynch","year":"2015","unstructured":"Lynch, R. M. et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci. Transl. Med. 7, 319ra206 (2015).","journal-title":"Sci. Transl. Med."},{"key":"412_CR64","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/cei.12692","volume":"182","author":"JE Ledgerwood","year":"2015","unstructured":"Ledgerwood, J. E. et al. Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin. Exp. Immunol. 182, 289\u2013301 (2015).","journal-title":"Clin. Exp. Immunol."},{"key":"412_CR65","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/nm.4268","volume":"23","author":"M Caskey","year":"2017","unstructured":"Caskey, M. et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat. Med. 23, 185\u2013191 (2017).","journal-title":"Nat. Med."},{"key":"412_CR66","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1126\/science.aaf1279","volume":"352","author":"CL Lu","year":"2016","unstructured":"Lu, C. L. et al. Enhanced clearance of HIV-1-infected cells by anti-HIV-1 broadly neutralizing antibodies in vivo. Science 352, 1001\u20131004 (2016).","journal-title":"Science"},{"key":"412_CR67","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1126\/science.aaf0972","volume":"352","author":"T Schoofs","year":"2016","unstructured":"Schoofs, T. et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science 352, 997\u20131001 (2016).","journal-title":"Science"},{"key":"412_CR68","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nature18929","volume":"535","author":"JF Scheid","year":"2016","unstructured":"Scheid, J. F. et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature 535, 556\u2013560 (2016).","journal-title":"Nature"},{"key":"412_CR69","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1084\/jem.20180936","volume":"215","author":"YZ Cohen","year":"2018","unstructured":"Cohen, Y. Z. et al. Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117. J. Exp. Med. 215, 2311\u20132324 (2018).","journal-title":"J. Exp. Med."},{"key":"412_CR70","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","volume":"375","author":"KJ Bar","year":"2016","unstructured":"Bar, K. J. et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N. Engl. J. Med. 375, 2037\u20132050 (2016).","journal-title":"N. Engl. J. Med."},{"key":"412_CR71","doi-asserted-by":"crossref","first-page":"e01883","DOI":"10.1128\/JVI.01883-17","volume":"92","author":"YZ Cohen","year":"2018","unstructured":"Cohen, Y. Z. et al. Neutralizing activity of broadly neutralizing anti-HIV-1 antibodies against Clade B clinical isolates produced in peripheral blood mononuclear cells. J. Virol. 92, e01883\u201317 (2018).","journal-title":"J. Virol."},{"key":"412_CR72","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41591-018-0186-4","volume":"24","author":"Y Bar-On","year":"2018","unstructured":"Bar-On, Y. et al. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nat. Med. 24, 1701\u20131707 (2018).","journal-title":"Nat. Med."},{"key":"412_CR73","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","volume":"561","author":"P Mendoza","year":"2018","unstructured":"Mendoza, P. et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature 561, 479\u2013484 (2018).","journal-title":"Nature"},{"key":"412_CR74","doi-asserted-by":"crossref","first-page":"18921","DOI":"10.1073\/pnas.1214785109","volume":"109","author":"B Moldt","year":"2012","unstructured":"Moldt, B. et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl Acad. Sci. USA 109, 18921\u201318925 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"412_CR75","doi-asserted-by":"crossref","first-page":"eaal1321","DOI":"10.1126\/scitranslmed.aal1321","volume":"9","author":"B Julg","year":"2017","unstructured":"Julg, B. et al. Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Sci. Transl. Med. 9, eaal1321 (2017).","journal-title":"Sci. Transl. Med."},{"key":"412_CR76","doi-asserted-by":"crossref","first-page":"e1002493","DOI":"10.1371\/journal.pmed.1002493","volume":"15","author":"MR Gaudinski","year":"2018","unstructured":"Gaudinski, M. R. et al. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A phase 1 open-label clinical trial in healthy adults. PLoS Med. 15, e1002493 (2018).","journal-title":"PLoS Med."},{"key":"412_CR77","first-page":"20160001","volume":"9","author":"PB Gilbert","year":"2017","unstructured":"Gilbert, P. B. et al. Basis and statistical design of the passive HIV-1 antibody mediated prevention (AMP) test-of-concept efficacy trials. Stat. Commun. Infect. Dis. 9, 20160001 (2017).","journal-title":"Stat. Commun. Infect. Dis."},{"key":"412_CR78","doi-asserted-by":"crossref","first-page":"e1006860","DOI":"10.1371\/journal.ppat.1006860","volume":"14","author":"K Wagh","year":"2018","unstructured":"Wagh, K. et al. Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections. PLoS Pathog. 14, e1006860 (2018).","journal-title":"PLoS Pathog."},{"key":"412_CR79","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1128\/JVI.06745-11","volume":"86","author":"NA Doria-Rose","year":"2012","unstructured":"Doria-Rose, N. A. et al. HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes. J. Virol. 86, 3393\u20133397 (2012).","journal-title":"J. Virol."},{"key":"412_CR80","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1128\/JVI.03136-14","volume":"89","author":"R Kong","year":"2015","unstructured":"Kong, R. et al. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes. J. Virol. 89, 2659\u20132671 (2015).","journal-title":"J. Virol."},{"key":"412_CR81","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.immuni.2018.04.030","volume":"48","author":"S Sengupta","year":"2018","unstructured":"Sengupta, S. & Siliciano, R. F. Targeting the latent reservoir for HIV-1. Immunity 48, 872\u2013895 (2018).","journal-title":"Immunity"},{"key":"412_CR82","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/387183a0","volume":"387","author":"TW Chun","year":"1997","unstructured":"Chun, T. W. et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 387, 183\u2013188 (1997).","journal-title":"Nature"},{"key":"412_CR83","doi-asserted-by":"crossref","first-page":"E7908","DOI":"10.1073\/pnas.1617789113","volume":"113","author":"JC Lorenzi","year":"2016","unstructured":"Lorenzi, J. C. et al. Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA. Proc. Natl Acad. Sci. USA 113, E7908\u2013E7916 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"412_CR84","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1084\/jem.20170193","volume":"214","author":"NN Hosmane","year":"2017","unstructured":"Hosmane, N. N. et al. Proliferation of latently infected CD4+ T cells carrying replication-competent HIV-1: potential role in latent reservoir dynamics. J. Exp. Med. 214, 959\u2013972 (2017).","journal-title":"J. Exp. Med."},{"key":"412_CR85","doi-asserted-by":"crossref","first-page":"E2575","DOI":"10.1073\/pnas.1720665115","volume":"115","author":"Z Wang","year":"2018","unstructured":"Wang, Z. et al. Expanded cellular clones carrying replication-competent HIV-1 persist, wax, and wane. Proc. Natl Acad. Sci. USA 115, E2575\u2013E2584 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"412_CR86","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nri3478","volume":"13","author":"BD Walker","year":"2013","unstructured":"Walker, B. D. & Yu, X. G. Unravelling the mechanisms of durable control of HIV-1. Nat. Rev. Immunol. 13, 487\u2013498 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"412_CR87","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/CMR.0b013e32832eabd5","volume":"19","author":"LV Kalialis","year":"2009","unstructured":"Kalialis, L. V., Drzewiecki, K. T. & Klyver, H. Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res. 19, 275\u2013282 (2009).","journal-title":"Melanoma Res."},{"key":"412_CR88","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1128\/JVI.68.7.4650-4655.1994","volume":"68","author":"RA Koup","year":"1994","unstructured":"Koup, R. A. et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650\u20134655 (1994).","journal-title":"J. Virol."},{"key":"412_CR89","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/328345a0","volume":"328","author":"BD Walker","year":"1987","unstructured":"Walker, B. D. et al. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 328, 345\u2013348 (1987).","journal-title":"Nature"},{"key":"412_CR90","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature14053","volume":"517","author":"K Deng","year":"2015","unstructured":"Deng, K. et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature 517, 381\u2013385 (2015).","journal-title":"Nature"},{"key":"412_CR91","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1073\/pnas.0500014102","volume":"102","author":"KM Dhodapkar","year":"2005","unstructured":"Dhodapkar, K. M. et al. Selective blockade of inhibitory Fcgamma receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells. Proc. Natl Acad. Sci. USA 102, 2910\u20132915 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"412_CR92","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"412_CR93","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1093\/infdis\/jiw618","volume":"215","author":"DM Margolis","year":"2017","unstructured":"Margolis, D. M. & Archin , N. M. Proviral latency, persistent human immunodeficiency virus infection, and the development of latency reversing agents. J. Infect. Dis. 215, S111\u2013S118 (2017).","journal-title":"J. Infect. Dis."},{"key":"412_CR94","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/s41591-018-0017-7","volume":"24","author":"LB Cohn","year":"2018","unstructured":"Cohn, L. B. et al. Clonal CD4+ T cells in the HIV-1 latent reservoir display a distinct gene profile upon reactivation. Nat. Med. 24, 604\u2013609 (2018).","journal-title":"Nat. Med."},{"key":"412_CR95","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.immuni.2017.09.014","volume":"47","author":"L Shan","year":"2017","unstructured":"Shan, L.et al. Transcriptional reprogramming during effector-to-memory transition renders CD4+ T cells permissive for latent HIV-1 infection. Immunity 47, 766\u2013775 e763 2017).","journal-title":"Immunity"},{"key":"412_CR96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11904-016-0296-x","volume":"13","author":"LR Cockerham","year":"2016","unstructured":"Cockerham, L. R., Hatano, H. & Deeks, S. G. Post-treatment controllers: role in HIV \u201ccure\u201d research. Curr. HIV\/AIDS Rep. 13, 1\u20139 (2016).","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"412_CR97","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/infdis\/jiy479","volume":"218","author":"G Namazi","year":"2018","unstructured":"Namazi, G. et al. The control of HIV after antiretroviral medication pause (CHAMP) study: posttreatment controllers identified from 14 clinical studies. J. Infect. Dis. 218, 1954\u20131963 (2018).","journal-title":"J. Infect. Dis."},{"key":"412_CR98","doi-asserted-by":"crossref","first-page":"e1003211","DOI":"10.1371\/journal.ppat.1003211","volume":"9","author":"A S\u00e1ez-Ciri\u00f3n","year":"2013","unstructured":"S\u00e1ez-Ciri\u00f3n, A. et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog. 9, e1003211 (2013).","journal-title":"PLoS Pathog."},{"key":"412_CR99","unstructured":"Scott-Algaram, D. et al. Post-treatment controllers have particular NK cells with high anti-HIV capacity: VISCONTI study. Conference on Retroviruses and Opportunistic Infections, abstr. 52 (2015)."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41591-019-0412-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-019-0412-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-019-0412-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:59:10Z","timestamp":1684605550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-019-0412-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":99,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["412"],"URL":"https:\/\/doi.org\/10.1038\/s41591-019-0412-8","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"8 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are patents on 3BNC117 and 10-1074, on which M.C.N is an inventor.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}